Nifty
:
19664.70
Sensex
:
65945.47
-9.85 (-0.05%)
-78.22 (-0.12%)
Nifty
Sensex
:
:
19664.70
65945.47
-9.85 (-0.05%)
-78.22 (-0.12%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
55/99

BSE: 500087 | NSE: CIPLA

NSE BSE
1163.65
26-Sep-2023
  • Open
  • High
  • Low
  • Previous Close
  •  1181.00
  •  1185.00
  •  1161.50
  •  1179.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1056359
  •  12380.33
  •  1277.90
  •  852.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 93,955.61
  • 30.20
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 92,911.35
  • 0.73%
  • 3.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.47%
  • 0.50%
  • 14.66%
  • FII
  • DII
  • Others
  • 25.5%
  • 21.82%
  • 4.05%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.38
  • 6.82
  • 5.90

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.87
  • 11.71
  • 3.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.19
  • 12.67
  • 5.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.14
  • 30.43
  • 31.11

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.53
  • 3.45
  • 3.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.33
  • 15.20
  • 16.33

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Net Sales
6,328.89
5,375.19
17.74%
5,739.30
5,260.33
9.11%
5,810.09
5,478.86
6.05%
5,828.54
5,519.80
5.59%
Expenses
4,834.98
4,231.84
14.25%
4,565.56
4,510.61
1.22%
4,402.54
4,247.89
3.64%
4,526.21
4,293.60
5.42%
EBITDA
1,493.91
1,143.35
30.66%
1,173.74
749.72
56.56%
1,407.55
1,230.97
14.34%
1,302.33
1,226.20
6.21%
EBIDTM
23.60%
21.27%
20.45%
14.25%
24.23%
22.47%
22.34%
22.21%
Other Income
136.29
103.43
31.77%
134.63
64.02
110.29%
114.44
91.29
25.36%
122.95
60.67
102.65%
Interest
16.39
17.81
-7.97%
34.36
18.10
89.83%
31.82
20.68
53.87%
25.55
38.00
-32.76%
Depreciation
239.21
254.41
-5.97%
346.22
290.31
19.26%
272.11
247.47
9.96%
299.37
253.06
18.30%
PBT
1,374.60
974.56
41.05%
745.37
447.83
66.44%
1,218.06
1,054.11
15.55%
1,100.36
995.81
10.50%
Tax
378.02
268.00
41.05%
222.25
71.11
212.54%
410.01
295.16
38.91%
302.60
283.81
6.62%
PAT
996.58
706.56
41.05%
523.12
376.72
38.86%
808.05
758.95
6.47%
797.76
712.00
12.04%
PATM
15.75%
13.14%
9.11%
7.16%
13.91%
13.85%
13.69%
12.90%
EPS
12.33
8.51
44.89%
6.51
4.49
44.99%
9.92
9.03
9.86%
9.78
8.82
10.88%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
23,706.82
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
Net Sales Growth
9.58%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
 
Cost Of Goods Sold
8,464.68
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
Gross Profit
15,242.14
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
GP Margin
64.29%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
Total Expenditure
18,329.29
17,762.83
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
Power & Fuel Cost
-
353.61
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
% Of Sales
-
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
Employee Cost
-
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
% Of Sales
-
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
Manufacturing Exp.
-
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
% Of Sales
-
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
General & Admin Exp.
-
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
% Of Sales
-
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
Selling & Distn. Exp.
-
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
% Of Sales
-
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
Miscellaneous Exp.
-
619.43
565.55
508.00
692.12
855.40
968.98
645.54
657.29
497.67
680.32
% Of Sales
-
2.72%
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
EBITDA
5,377.53
4,990.29
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
EBITDA Margin
22.68%
21.93%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
Other Income
508.31
512.13
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
Interest
108.12
109.54
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
Depreciation
1,156.91
1,172.11
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
372.64
PBT
4,438.39
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
Tax
1,312.88
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
Tax Rate
29.58%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
PAT
3,125.51
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
PAT before Minority Interest
3,111.90
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
Minority Interest
-13.61
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
PAT Margin
13.18%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
PAT Growth
22.37%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
 
EPS
38.80
34.81
31.40
30.01
19.79
19.18
17.54
12.58
17.03
14.97
17.39

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
Share Capital
161.43
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
Total Reserves
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
Non-Current Liabilities
183.53
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
Secured Loans
332.46
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
Unsecured Loans
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
Long Term Provisions
102.16
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
Current Liabilities
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
Trade Payables
2,457.05
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
Other Current Liabilities
1,085.07
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
Short Term Borrowings
187.90
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
Short Term Provisions
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
Total Liabilities
28,930.34
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
Net Block
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
Gross Block
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
Accumulated Depreciation
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
Non Current Assets
11,731.79
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
Capital Work in Progress
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
Non Current Investment
572.52
355.63
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
Long Term Loans & Adv.
845.11
736.39
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
Other Non Current Assets
60.38
383.22
102.51
77.61
166.82
255.71
210.06
176.54
168.88
158.89
Current Assets
16,805.06
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
Current Investments
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
Inventories
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
Sundry Debtors
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
Cash & Bank
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
Other Current Assets
2,937.15
305.56
347.54
442.02
1,566.48
1,599.13
1,226.01
1,223.17
858.67
630.63
Short Term Loans & Adv.
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
Net Current Assets
11,771.79
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
Total Assets
28,536.85
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
PBT
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
Adjustment
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
Changes in Working Capital
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
Cash after chg. in Working capital
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
Net Fixed Assets
-637.57
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
Net Investments
-935.67
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
Others
-815.27
-425.89
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
Cash from Financing Activity
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
Net Cash Inflow / Outflow
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
Opening Cash & Equivalents
658.11
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
143.01
Closing Cash & Equivalent
561.33
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26
175.76

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
289.24
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
ROA
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
ROE
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
ROCE
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
Fixed Asset Turnover
1.81
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
1.47
Receivable days
44.13
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
Inventory Days
61.98
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
Payable days
109.80
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
44.93
Cash Conversion Cycle
-3.69
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
107.41
Total Debt/Equity
0.02
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
Interest Cover
37.87
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • USFDA issues 5 inspectional observations to New York facility of Cipla’s arm
    21st Sep 2023, 10:23 AM

    The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time

    Read More
  • Cipla’s arm to acquire 100% stake in Actor Pharma
    5th Sep 2023, 09:39 AM

    This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost synergies in the South African market

    Read More
  • Cipla’s associate company incorporates wholly owned subsidiary
    27th Jul 2023, 09:49 AM

    The creation of Pactiv as a separate entity allows GoApptiv to segregate its business into distinct sectors i.e., technology and pharmaceuticals

    Read More
  • Cipla reports 41% rise in Q1 consolidated net profit
    26th Jul 2023, 15:51 PM

    Total consolidated income of the company increased by 18.01% at Rs 6,465.18 crore for Q1FY24

    Read More
  • Cipla - Quarterly Results
    26th Jul 2023, 15:16 PM

    Read More
  • Cipla's arm recalling six batches of Albuterol Sulfate inhalation Aerosol in US
    10th Jul 2023, 16:54 PM

    These six batches were distributed nationwide to wholesalers and retailers

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.